DE60134874D1 - Benzodiazepin-derivate als gamma-secretase inhibitoren - Google Patents
Benzodiazepin-derivate als gamma-secretase inhibitorenInfo
- Publication number
- DE60134874D1 DE60134874D1 DE60134874T DE60134874T DE60134874D1 DE 60134874 D1 DE60134874 D1 DE 60134874D1 DE 60134874 T DE60134874 T DE 60134874T DE 60134874 T DE60134874 T DE 60134874T DE 60134874 D1 DE60134874 D1 DE 60134874D1
- Authority
- DE
- Germany
- Prior art keywords
- gamma
- secretase inhibitors
- benzodiazepine derivatives
- compounds
- benzodiazepine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 title 1
- 150000001557 benzodiazepines Chemical class 0.000 title 1
- 239000003540 gamma secretase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0025173.6A GB0025173D0 (en) | 2000-10-13 | 2000-10-13 | Therapeutic agents |
PCT/GB2001/004474 WO2002030912A1 (en) | 2000-10-13 | 2001-10-08 | Benzodiazepine derivatives as inhibitors of gamma secretase |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60134874D1 true DE60134874D1 (de) | 2008-08-28 |
Family
ID=9901256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60134874T Expired - Fee Related DE60134874D1 (de) | 2000-10-13 | 2001-10-08 | Benzodiazepin-derivate als gamma-secretase inhibitoren |
Country Status (9)
Country | Link |
---|---|
US (1) | US6995155B2 (de) |
EP (1) | EP1326849B1 (de) |
JP (1) | JP2004511474A (de) |
AT (1) | ATE401314T1 (de) |
AU (1) | AU2001292126A1 (de) |
CA (1) | CA2424812A1 (de) |
DE (1) | DE60134874D1 (de) |
GB (1) | GB0025173D0 (de) |
WO (1) | WO2002030912A1 (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001125908A (ja) * | 1999-10-26 | 2001-05-11 | Sony Corp | 入力装置および方法 |
GB0012671D0 (en) * | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
ATE485006T1 (de) * | 2000-09-08 | 2010-11-15 | Abbott Vascular Inc | Vorrichtung zum orten eines punktierten blutgefässes |
US7060698B2 (en) | 2003-05-19 | 2006-06-13 | Hoffmann-La Roche Inc. | Benzoxazepinone derivatives |
WO2005090319A1 (en) * | 2004-03-19 | 2005-09-29 | Arrow Therapeutics Limited | Process for preparing benzodiazepines |
US20060084672A1 (en) * | 2004-10-20 | 2006-04-20 | The Hospital For Sick Children | Method for modification of y-secretase activity through inhibition of Fkbp13 |
ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
WO2011053822A2 (en) | 2009-11-01 | 2011-05-05 | The Brigham And Women's Hospital, Inc. | Notch inhibition in the treatment and prevention of obesity and metabolic syndrome |
WO2007103114A2 (en) | 2006-03-07 | 2007-09-13 | The Brigham & Women's Hospital, Inc. | Notch inhibition in the treatment or prevention of atherosclerosis |
WO2008099210A2 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
JP5539221B2 (ja) | 2007-12-21 | 2014-07-02 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 選択的アンドロゲン受容体モジュレーター(sarm)およびその使用 |
EP2291181B9 (de) | 2008-04-18 | 2013-09-11 | University College Dublin National University Of Ireland, Dublin | Captodiamine zur Behandlung von depressionartigen Symptomen |
US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
US20120129189A1 (en) * | 2009-07-17 | 2012-05-24 | Chulan Kwon | Methods of Controlling Cell Proliferation |
UA109417C2 (uk) | 2009-10-14 | 2015-08-25 | Мерк Шарп Енд Доме Корп. | ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ |
WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
CN107090456B (zh) | 2010-08-02 | 2022-01-18 | 瑟纳治疗公司 | 使用短干扰核酸的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1基因表达的抑制 |
US9029341B2 (en) | 2010-08-17 | 2015-05-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) |
EP2613782B1 (de) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
EP3327125B1 (de) | 2010-10-29 | 2020-08-05 | Sirna Therapeutics, Inc. | Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina) |
US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
WO2013059302A1 (en) | 2011-10-17 | 2013-04-25 | Nationwide Children's Hospital, Inc. | Products and methods for aortic abdominal aneurysm |
EP2770987B1 (de) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Neue verbindungen als erk-hemmer |
EP2844261B1 (de) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | Sina-zusammensetzungen |
EP2900241B1 (de) | 2012-09-28 | 2018-08-08 | Merck Sharp & Dohme Corp. | Neuartige verbindungen als erk-hemmer |
WO2014085216A1 (en) | 2012-11-28 | 2014-06-05 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
AR094116A1 (es) | 2012-12-20 | 2015-07-08 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de hdm2 |
WO2014096212A1 (en) * | 2012-12-20 | 2014-06-26 | Janssen Pharmaceutica Nv | NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-α]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS |
CN104936958B (zh) | 2013-01-17 | 2019-07-26 | 詹森药业有限公司 | 作为γ分泌酶调节剂的新颖的经取代的吡啶并-哌嗪酮衍生物 |
EP2951180B1 (de) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8-substituierte purine als hdm2-inhibitoren |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
US10441567B2 (en) | 2014-01-17 | 2019-10-15 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
WO2018071283A1 (en) | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
EP3706747A4 (de) | 2017-11-08 | 2021-08-04 | Merck Sharp & Dohme Corp. | Prmt5-inhibitoren |
JP2021523189A (ja) * | 2018-05-15 | 2021-09-02 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | ビスフルオロアルキル−1,4−ベンゾジアゼピノン化合物を含む組成物およびその使用方法 |
EP3823672A1 (de) | 2018-07-19 | 2021-05-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Kombinationen zur behandlung von krebs |
WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
EP3833668A4 (de) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | Prmt5-inhibitoren |
MX2022007535A (es) | 2019-12-17 | 2022-09-23 | Merck Sharp & Dohme Llc | Inhibidores de prmt5. |
US20230416830A1 (en) | 2020-11-16 | 2023-12-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating uveal melanoma |
WO2024049931A1 (en) | 2022-09-02 | 2024-03-07 | Merck Sharp & Dohme Llc | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof |
WO2024091437A1 (en) | 2022-10-25 | 2024-05-02 | Merck Sharp & Dohme Llc | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
TW202430140A (zh) | 2022-12-14 | 2024-08-01 | 美商默沙東有限責任公司 | 奧里斯他汀(auristatin)連接子藥物(payload)、醫藥組合物及其用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5426185A (en) | 1993-11-22 | 1995-06-20 | Merck & Co., Inc. | Antiarrhythmic benzodiazepines |
ZA9711537B (en) | 1996-12-23 | 1998-06-25 | Athena Neurosciences Inc Eli L | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds. |
FR2782997A1 (fr) | 1998-09-08 | 2000-03-10 | Hoechst Marion Roussel Inc | Nouveaux derives de la benzodiazepinone, procede de preparation et intermediaires de ce procede, application a titre de medicaments et compositions pharmaceutiques les renfermant |
BR9917082A (pt) | 1998-12-24 | 2001-11-06 | Du Pont Pharm Co | Compostos inibidores da produção de proteìnas a"beta", método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, composição farmacêutica e, método de inibição da atividade de y-secretase |
GB0012671D0 (en) | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
-
2000
- 2000-10-13 GB GBGB0025173.6A patent/GB0025173D0/en not_active Ceased
-
2001
- 2001-08-08 US US10/399,231 patent/US6995155B2/en not_active Expired - Fee Related
- 2001-10-08 EP EP01972352A patent/EP1326849B1/de not_active Expired - Lifetime
- 2001-10-08 AU AU2001292126A patent/AU2001292126A1/en not_active Abandoned
- 2001-10-08 AT AT01972352T patent/ATE401314T1/de not_active IP Right Cessation
- 2001-10-08 JP JP2002534298A patent/JP2004511474A/ja not_active Withdrawn
- 2001-10-08 DE DE60134874T patent/DE60134874D1/de not_active Expired - Fee Related
- 2001-10-08 WO PCT/GB2001/004474 patent/WO2002030912A1/en active IP Right Grant
- 2001-10-08 CA CA002424812A patent/CA2424812A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040024203A1 (en) | 2004-02-05 |
US6995155B2 (en) | 2006-02-07 |
WO2002030912A1 (en) | 2002-04-18 |
EP1326849A1 (de) | 2003-07-16 |
CA2424812A1 (en) | 2002-04-18 |
GB0025173D0 (en) | 2000-11-29 |
EP1326849B1 (de) | 2008-07-16 |
JP2004511474A (ja) | 2004-04-15 |
ATE401314T1 (de) | 2008-08-15 |
AU2001292126A1 (en) | 2002-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE401314T1 (de) | Benzodiazepin-derivate als gamma-secretase inhibitoren | |
ATE299890T1 (de) | Inhibitoren von gamma-secretase | |
ATE386028T1 (de) | Zyklohexylsulfone als gamma-sekretase-inhibitoren | |
ATE302753T1 (de) | Sulfamide als gamma-secretase-inhibitoren | |
ATE346039T1 (de) | Sulfonamido-substituierte verbrückte bicycloalkylderivative | |
ATE464287T1 (de) | Cyclohexyl-sulphone als gamma-sekretase- inhibitoren | |
ATE368031T1 (de) | Neue gamma secretase inhibitoren | |
GB0225474D0 (en) | Therapeutic agents | |
DE60312017D1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
DE60218458D1 (de) | Isochinolinon derivate als parp inhibitoren | |
GB0225475D0 (en) | Therapeutic agents | |
ATE427300T1 (de) | Heterocyclisch substituierte amide als calpainhemmer | |
DE60121461D1 (de) | Kondensierte pyridoindolderivate | |
ATE300543T1 (de) | Kondensierte pyrazindionderivate als pde5 inhibitore | |
DE60115466D1 (de) | Wirkstoffvorläufer von imidazopyridin-derivaten | |
ATE365735T1 (de) | Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel | |
DE60112960D1 (de) | Kondensierte pyridoindolderivate | |
BG105710A (en) | 5ht1 antagonists for antidepressant therapy | |
TNSN04034A1 (en) | Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof | |
DE60122559D1 (de) | Indolderivate als pde5-inhibitoren | |
NZ516620A (en) | 1,4-substituted 4,4-diaryl cyclohexanes | |
DE60121048D1 (de) | PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE | |
GB0522908D0 (en) | Therapeutic agents | |
DE60136706D1 (de) | Ycin-acryloyl derivate und antimetabolische mitteln | |
SE9902596D0 (sv) | Pharmaceutically active compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |